Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
MaxCyte ( (MXCT) ) has shared an announcement.
MaxCyte, Inc. has announced a change in its major holdings, with BlackRock, Inc. increasing its voting rights in the company to 7.80%. This adjustment in holdings reflects BlackRock’s strategic interest in MaxCyte, potentially influencing the company’s governance and future strategic decisions, while also highlighting the confidence of major investors in MaxCyte’s market position and growth potential.
More about MaxCyte
MaxCyte, Inc. operates in the biotechnology industry, focusing on cell-based therapies and related technologies. The company provides cell engineering platforms that enable the development of advanced therapeutics, catering primarily to the healthcare and pharmaceutical sectors.
Find detailed analytics on MXCT stock on TipRanks’ Stock Analysis page.